Compare $AIM vs $APUS | Chartloom

Compare

$AIM vs $APUS

AIM ImmunoTech Inc · Apimeds Pharmaceuticals US Inc

AIM

AIM ImmunoTech Inc

APUS

Apimeds Pharmaceuticals US Inc

Compare $AIM vs $APUS

Comparing AIM ImmunoTech Inc and Apimeds Pharmaceuticals US Inc

AIMAIM ImmunoTech Inc

APUSApimeds Pharmaceuticals US Inc

AIMAIM ImmunoTech Inc

Market cap

$5M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-21.5%

YTD performance

-84.4%

52W performance

-92.8%

FCF yield

-292.9%

APUSApimeds Pharmaceuticals US Inc

Market cap

$8M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-69.8%

52W performance

-75.9%

FCF yield

-70.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AIM

APUS

Detailed metrics comparison

AIM

AIM ImmunoTech Inc

APUS

Apimeds Pharmaceuticals US Inc

Market Cap

AIM$5M

APUS$8M

Enterprise Value

AIM$-1M

APUS$22M

Price

AIM$0.18

APUS$5.02

P/E Ratio

AIMN/A

APUSN/A

P/S Ratio

AIM52.52x

APUS0.00x

EV/Sales

AIM-13.57x

APUS0.00x

EV/EBITDA

AIM0.00x

APUS0.00x

P/B Ratio

AIM0.91x

APUS0.05x

P/FCF Ratio

AIMN/A

APUSN/A

EV/FCF

AIM0.09x

APUS-4.06x

PEG Ratio

AIMN/A

APUSN/A

Forward P/E (NTM)

AIMN/A

APUSN/A

Forward P/S (NTM)

AIMN/A

APUSN/A

Revenue (TTM)

AIM$95K

APUS$0

Revenue Growth (YoY)

AIM-21.5%

APUSN/A

Forward Rev Growth

AIM-32.4%

APUS0.0%

Gross Margin (TTM)

AIM-23.2%

APUS0.0%

Operating Margin (TTM)

AIM0.0%

APUS0.0%

EBITDA Margin (TTM)

AIM-10985.3%

APUS0.0%

Net Margin (TTM)

AIM-15021.1%

APUS0.0%

FCF Margin (TTM)

AIM-15385.3%

APUSN/A

Net Income (TTM)

AIM$-14M

APUS$-58M

FCF (TTM)

AIM$-15M

APUS$-5M

EPS (TTM)

AIM-$0.83

APUS-$33.95

ROE (TTM)

AIM-13803.0%

APUS-5898.0%

ROA (TTM)

AIM-17514.0%

APUS-5261.0%

ROIC (TTM)

AIM-7694.0%

APUS-5458.0%

Cash

AIM$10M

APUS$278K

Debt

AIM$4M

APUS$14M

Net Cash/Debt

AIM$6M

APUS$-14M

Current Ratio (TTM)

AIM2.11x

APUS0.51x

Quick Ratio (TTM)

AIM2.01x

APUS0.40x

Debt/Equity (TTM)

AIM0.47x

APUS0.14x

Debt/Assets (TTM)

AIM0.0%

APUS0.0%

Interest Coverage (TTM)

AIMN/A

APUSN/A

Net Debt/EBITDA (TTM)

AIM0.00x

APUS0.00x

Beta

AIM1.35

APUS2.60

52W Performance

AIM-92.8%

APUS-75.9%

YTD Performance

AIM-84.4%

APUS-69.8%

% from 52W High

AIM-93.6%

APUS-91.6%

% from 52W Low

AIM8.4%

APUS232.5%

Asset Turnover (TTM)

AIM0.01x

APUS0.00x

FCF Yield (TTM)

AIM-292.9%

APUS-70.6%

Earnings Yield (TTM)

AIM-286.0%

APUS-767.4%

Dividend Yield (TTM)

AIMN/A

APUSN/A

Rule of 40

AIM-15,406.8

APUS0.0

EV/GP/RG

AIMN/A

APUSN/A

Ticker research

View AIM research View APUS research

Metric	AIM AIM ImmunoTech Inc	APUS Apimeds Pharmaceuticals US Inc
Market & Valuation
Market Cap	$5M	$8M
Enterprise Value	$-1M	$22M
Price	$0.18	$5.02
P/E Ratio	N/A	N/A
P/S Ratio	52.52x	0.00x
EV/Sales	-13.57x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.91x	0.05x
P/FCF Ratio	N/A	N/A
EV/FCF	0.09x	-4.06x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$95K	$0
Revenue Growth (YoY)	-21.5%	N/A
Forward Rev Growth	-32.4%	0.0%
Profitability
Gross Margin (TTM)	-23.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-10985.3%	0.0%
Net Margin (TTM)	-15021.1%	0.0%
FCF Margin (TTM)	-15385.3%	N/A
Net Income (TTM)	$-14M	$-58M
FCF (TTM)	$-15M	$-5M
EPS (TTM)	-$0.83	-$33.95
ROE (TTM)	-13803.0%	-5898.0%
ROA (TTM)	-17514.0%	-5261.0%
ROIC (TTM)	-7694.0%	-5458.0%
Financial Health
Cash	$10M	$278K
Debt	$4M	$14M
Net Cash/Debt	$6M	$-14M
Current Ratio (TTM)	2.11x	0.51x
Quick Ratio (TTM)	2.01x	0.40x
Debt/Equity (TTM)	0.47x	0.14x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.35	2.60
52W Performance	-92.8%	-75.9%
YTD Performance	-84.4%	-69.8%
% from 52W High	-93.6%	-91.6%
% from 52W Low	8.4%	232.5%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-292.9%	-70.6%
Earnings Yield (TTM)	-286.0%	-767.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-15,406.8	0.0
EV/GP/RG	N/A	N/A
Ticker research	View AIM research	View APUS research

Valuation

P/S Ratio

APUS

0.00x

AIM

52.52x

EV/FCF

APUS

-4.06x

AIM

0.09x

Growth & revenue

Revenue Growth TTM

AIM

-21.5%

Forward Revenue Growth

APUS

0.0%

AIM

-32.4%

Profitability & performance

Gross Margin

APUS

0.0%

AIM

-23.2%

ROE

APUS

-5898.0%

AIM

-13803.0%

FCF Yield %

APUS

-70.6%

AIM

-292.9%

52-Week Performance

APUS

-75.9%

AIM

-92.8%

Detailed metrics comparison

AIM

AIM ImmunoTech Inc

APUS

Apimeds Pharmaceuticals US Inc

Market Cap

AIM$5M

APUS$8M

Enterprise Value

AIM$-1M

APUS$22M

Price

AIM$0.18

APUS$5.02

P/E Ratio

AIMN/A

APUSN/A

P/S Ratio

AIM52.52x

APUS0.00x

EV/Sales

AIM-13.57x

APUS0.00x

EV/EBITDA

AIM0.00x

APUS0.00x

P/B Ratio

AIM0.91x

APUS0.05x

P/FCF Ratio

AIMN/A

APUSN/A

EV/FCF

AIM0.09x

APUS-4.06x

PEG Ratio

AIMN/A

APUSN/A

Forward P/E (NTM)

AIMN/A

APUSN/A

Forward P/S (NTM)

AIMN/A

APUSN/A

Revenue (TTM)

AIM$95K

APUS$0

Revenue Growth (YoY)

AIM-21.5%

APUSN/A

Forward Rev Growth

AIM-32.4%

APUS0.0%

Gross Margin (TTM)

AIM-23.2%

APUS0.0%

Operating Margin (TTM)

AIM0.0%

APUS0.0%

EBITDA Margin (TTM)

AIM-10985.3%

APUS0.0%

Net Margin (TTM)

AIM-15021.1%

APUS0.0%

FCF Margin (TTM)

AIM-15385.3%

APUSN/A

Net Income (TTM)

AIM$-14M

APUS$-58M

FCF (TTM)

AIM$-15M

APUS$-5M

EPS (TTM)

AIM-$0.83

APUS-$33.95

ROE (TTM)

AIM-13803.0%

APUS-5898.0%

ROA (TTM)

AIM-17514.0%

APUS-5261.0%

ROIC (TTM)

AIM-7694.0%

APUS-5458.0%

Cash

AIM$10M

APUS$278K

Debt

AIM$4M

APUS$14M

Net Cash/Debt

AIM$6M

APUS$-14M

Current Ratio (TTM)

AIM2.11x

APUS0.51x

Quick Ratio (TTM)

AIM2.01x

APUS0.40x

Debt/Equity (TTM)

AIM0.47x

APUS0.14x

Debt/Assets (TTM)

AIM0.0%

APUS0.0%

Interest Coverage (TTM)

AIMN/A

APUSN/A

Net Debt/EBITDA (TTM)

AIM0.00x

APUS0.00x

Beta

AIM1.35

APUS2.60

52W Performance

AIM-92.8%

APUS-75.9%

YTD Performance

AIM-84.4%

APUS-69.8%

% from 52W High

AIM-93.6%

APUS-91.6%

% from 52W Low

AIM8.4%

APUS232.5%

Asset Turnover (TTM)

AIM0.01x

APUS0.00x

FCF Yield (TTM)

AIM-292.9%

APUS-70.6%

Earnings Yield (TTM)

AIM-286.0%

APUS-767.4%

Dividend Yield (TTM)

AIMN/A

APUSN/A

Rule of 40

AIM-15,406.8

APUS0.0

EV/GP/RG

AIMN/A

APUSN/A

Ticker research

View AIM research View APUS research

Metric	AIM AIM ImmunoTech Inc	APUS Apimeds Pharmaceuticals US Inc
Market & Valuation
Market Cap	$5M	$8M
Enterprise Value	$-1M	$22M
Price	$0.18	$5.02
P/E Ratio	N/A	N/A
P/S Ratio	52.52x	0.00x
EV/Sales	-13.57x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.91x	0.05x
P/FCF Ratio	N/A	N/A
EV/FCF	0.09x	-4.06x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$95K	$0
Revenue Growth (YoY)	-21.5%	N/A
Forward Rev Growth	-32.4%	0.0%
Profitability
Gross Margin (TTM)	-23.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-10985.3%	0.0%
Net Margin (TTM)	-15021.1%	0.0%
FCF Margin (TTM)	-15385.3%	N/A
Net Income (TTM)	$-14M	$-58M
FCF (TTM)	$-15M	$-5M
EPS (TTM)	-$0.83	-$33.95
ROE (TTM)	-13803.0%	-5898.0%
ROA (TTM)	-17514.0%	-5261.0%
ROIC (TTM)	-7694.0%	-5458.0%
Financial Health
Cash	$10M	$278K
Debt	$4M	$14M
Net Cash/Debt	$6M	$-14M
Current Ratio (TTM)	2.11x	0.51x
Quick Ratio (TTM)	2.01x	0.40x
Debt/Equity (TTM)	0.47x	0.14x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.35	2.60
52W Performance	-92.8%	-75.9%
YTD Performance	-84.4%	-69.8%
% from 52W High	-93.6%	-91.6%
% from 52W Low	8.4%	232.5%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-292.9%	-70.6%
Earnings Yield (TTM)	-286.0%	-767.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-15,406.8	0.0
EV/GP/RG	N/A	N/A
Ticker research	View AIM research	View APUS research